Novozymes A/S
DUS:NZM2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
Novozymes A/S
DUS:NZM2
|
DK |
|
H
|
HCA Healthcare Inc
F:2BH
|
US |
|
Warner Bros Discovery Inc
F:J5A
|
US |
|
Aena SME SA
OTC:ANNSF
|
ES |
|
Duke Energy Corp
NYSE:DUK
|
US |
|
B
|
Baidu Inc
XHAM:B1CB
|
CN |
|
A
|
AstraZeneca PLC
XHAM:ZEG
|
UK |
|
Stora Enso Oyj
OTC:SEOFF
|
FI |
|
M
|
Meta Platforms Inc
XMUN:FB2A
|
US |
Wall St Price Targets
NZM2 Price Targets Summary
Novozymes A/S
According to Wall Street analysts, the average 1-year price target for NZM2 is 63.37 EUR with a low forecast of 51.3 EUR and a high forecast of 77.47 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is NZM2's stock price target?
Price Target
63.37
EUR
According to Wall Street analysts, the average 1-year price target for NZM2 is 63.37 EUR with a low forecast of 51.3 EUR and a high forecast of 77.47 EUR.
What is the Revenue forecast for Novozymes A/S?
Projected CAGR
-55%
Over the last 7 years, the compound annual growth rate for Revenue has been 3%. The projected CAGR for the next 2 years is -55%.
What is the Net Income forecast for Novozymes A/S?
Projected CAGR
-56%
Over the last 7 years, the compound annual growth rate for Net Income has been 0%. The projected CAGR for the next 2 years is -56%.
